Selpercatinib is a selective RET inhibitor that is currently FDA approved in patients with advanced medullary thyroid carcinoma and RET mutations and in RET fusion-driven thyroid cancer regardless of histology. The gene discussed is RET; the disease is thyroid gland carcinoma.